Hypertension, inflammation and T lymphocytes are increased in a rat model of HELLP syndrome

Hypertension in Pregnancy

Volumn 33, Issue 1, 2014, Pages 41-54

  Wallace, Kedra ^a   Morris, Rachael ^a   Kyle, Patrick B ^b   Cornelius, Denise ^a   Darby, Marie ^a   Scott, Jeremy ^a   Moseley, Janae ^a   Chatman, Krystal ^a   Lamarca, Babbette ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Angiogenic factors; CD4; CD8; HELLP syndrome; Hypertension; Inflammation; Preeclampsia; T lymphocytes

Indexed keywords

ENDOGLIN; INTERLEUKIN 17; INTERLEUKIN 6; LACTATE DEHYDROGENASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 1; ENDOGLIN PROTEIN, RAT; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BLOOD LEVEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; FEMALE; HELLP SYNDROME; HEMOLYSIS; HYPERTENSION; HYPERTRANSAMINASEMIA; INFLAMMATION; INFUSION; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; T LYMPHOCYTE; THROMBOCYTE COUNT; ANIMAL; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED; DISEASE MODEL; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; SPRAGUE DAWLEY RAT; TH1 CELL;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; FEMALE; HELLP SYNDROME; INTERLEUKIN-17; INTERLEUKIN-6; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84891541714     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.3109/10641955.2013.835820     Document Type: Article

References (60)

1. Geary M. The HELLP syndrome. Br J Obstet Gynaecol 1997;104:887-91. (Pubitemid 27309917)
2. Karumanchi S, Maynard S, Stillman I, et al. Preeclampsia: a renal perspective. Kidney Int 2005;67:2101-13. (Pubitemid 41623372)
3. Sibai B. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much do about nothing? Am J Obstet Gynecol 1990;162:311-16. (Pubitemid 20068487)
4. Keiser S, Owens M, Parrish M, et al. HELLP syndrome with and without eclampsia. Am J Perinatol 2011;28:187-94.
5. Martin Jr. J, Magann E, Isler C. HELLP syndrome: the scope of disease and treatment. Hypertens Pregn 2003;1:141-88.
6. Abildgaard U, Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obstet Gynecol Reprod Biol 2013;166:117-23.
7. Sibai B. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes and low platelet count. Obstet Gynecol 2004;103:981-91. (Pubitemid 40459001)
8. Prusac I, Zekic T, Roje D. Apoptosis, proliferation and Fas ligand expression in placental trophoblast from pregnancies complicated by HELLP syndrome for preeclampsia. Acta Obstet Gynecol Scand 2011;90:1157-63.
9. Martin Jr. J, Rinehart B, May W, et al. The spectrum of severe preeclampsia: comparative analysis by HELLP syndrome classification. Am J Obstet Gynecol 1999;180:1373-84.
10. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A review. BMC Pregn Childbirth 2009;9:8 (1-15).
11. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-9. (Pubitemid 43865232)
12. Tranquilli A, Landi B, Corradetti A, et al. Inflammatory cytokines patterns in the placenta of pregnancies complicated by HELLP (hemolysis, elevated liver enzyme, and low platelet) syndrome. Cytokine 2007;40:82-8. (Pubitemid 350180524)
13. van Runnard Heimel P, Kavelaars A, Heijnen C, et al. HELLP syndrome is associated with an increased inflammatory response, which may be inhibited by administration of prednisolone. Hypertens Pregn 2008;27:253-65.
14. Marusic J, Prusac I, Tomas S, et al. Expression of inflammatory cytokines in placentas from pregnancies complicated with preeclampsia and HELLP syndrome. J Matern-Fetal Neonatal Med 2013;26:680-5.
15. Wallace K, Martin Jr. J, Tam Tam K, et al. Seeking the mechanisms of action for corticosteroids in HELLP syndrome: SMASH study. Am J Obstet Gynecol 2013;208: e1-8.
16. LaMarca B, Bennett W, Alexander B, et al. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. Hypertension 2005;46:1022-5.
17. Roberts L, LaMarca B, Fournier L, et al. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension 2006;47:615-18. (Pubitemid 43843885)
18. LaMarca B, Ryan M, Gilbert J, et al. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep 2007;9:480-5.
19. Murphy S, LaMarca B, Cockrell K, Granger J. Role of endothelin in mediating soluble fms-like tyrosine kinase 1 induced hypertension in pregnant rats. Hypertension 2010;55:394-8.
20. Wallace K, Richards S, Dhillion P, et al. CD4+ T Helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy. Hypertension 2011; 57:949-55.
21. Wallace K, Novotny S, Heath J, et al. Hypertension in response to CD4+ T cells from reduced uterine perfusion pregnant rats is associated with activation of the endothelin-1 system. Am J Physiol Regul Integr Comp Physiol 2012;303:R144-9.
22. LaMarca B, Gilbert J, Granger J. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension 2008;51: 982-8. (Pubitemid 351398991)
23. Lamarca B, Wallace K, Herse F, et al. Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes. Hypertension 2011;57: 864-71.
24. Lamarca B. Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia. Minerva Ginecol 2012;64:309-20.
25. Isler C, Bennett W, Rinewalt A, et al. Evaluation of a rat model of preeclampsia for HELLP syndrome characteristics. J Soc Gynecol Investig 2003;10:151-3. (Pubitemid 36434147)
26. Zenclussen A, Fest S, Joachim R, et al. Introducing a mouse model for preeclampsia: adoptive transfer of activated Th1 cells leads to pre-eclampsia-like symptoms exclusively in pregnant mice. Eur J Immunol 2004;34:377-87. (Pubitemid 39255948)
27. Prins J, Boelens H, Heimweg J, et al. Preeclampsia is associated with lower percentages of regulatory T cells in maternal blood. Hypertens Pregn 2009;28: 300-11.
28. Toldi G, Svec P, Vasarhelyi B, et al. Decreased number of FoxP3+ regulatory T cells in preeclampsia. Acta Obstet Gynecol Scand 2008;87:1229-33.
29. Darmochwal-Kolarz D, Kludka-Sternik M, Tabarkiewicz J, et al. The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia. J Reprod Immunol 2012;93:75-81.
30. Novotny S, Wallace K, Heath J, et al. Activating autoantibodies to the angiotensin II type 1 receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats. Am J Physiol Regul Integrat Comparat Physiol 2012;301:R1197-201.
31. Roberts J, Taylor R, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991;4: 700-8.
32. Kupferminc M, Peaceman A, Wigton T, et al. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol 1994;170:1752-7.
33. Dechend R, Homuth V, Wallukat G, et al. Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia. J Soc Gynecol Investig 2006;13: 79-86. (Pubitemid 43155838)
34. Zhou C, Ahmad S, Mi T, et al. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 2008;51: 1010-19. (Pubitemid 351398948)
35. Aggarwal P, Chandel N, Jain V, Jha V. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Human Hypertens 2012;26:236-41.
36. George E, Granger J. Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1. Hypertension 2012;60:507-11.
37. Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol 2013;94:247-57.
38. Mai J, Wang H, Yang X. Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity. Frontiers Biosci 2010;15:986-1006.
39. Dhillion P, Wallace K, Scott J, et al. IL-17 mediated oxidative stress is an important stimulator of AT1-AA and hypertension during pregnancy. Am J Physiol - Regulat Integrat Comparat Physiol 2012;303:R353-8.
40. Saito S, Nakashima A, Ito M, Shima T. Clinical implication of recent advances in our understanding of IL-17 and reproductive immunology. Expert Rev Clin Immunol 2011;7:649-57.
41. Santner-Nanan B, Peek M, Khanam R, et al. Systemic increase in the ratio between FoxP3+ and IL-17 producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J Immunol 2009;183:7023-30.
42. Saito S, Sakai M. Th1/Th2 balance in preeclampsia. J Reprod Immunol 2003;59: 161-73. (Pubitemid 36945234)
43. LaMarca B, Wallace K, Granger J. Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Curr Opin Pharmacol 2011;11:175-9.
44. George E, Arany M, Cockrell K, et al. Induction of heme oxygenase-1 attenuates sFlt-1 induced hypertension in pregnant rats. Am J Physiol Regul Integr Comp Physiol 2011;301:R1495-500.
45. Murphy S, Lamarca B, Cockrell K, et al. L-arginine supplementation abolishes the blood pressure and endothelin response to chronic increases in plasma sFlt- 1 in pregnant rats. Am J Physiol Regulat Integr Comp Physiol 2012;302: R259-63.
46. Bussen S, Sutterlin M, Steck T. Plasma endothelin and big endothelin levels in women with severe preeclampsia or HELLP-syndrome. Arch Gynecol Obstet 1999; 262:113-19. (Pubitemid 29197074)
47. Hulstein J, Van Runnard Heimel P, Franx A, et al. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Thrombosis Haemostasis 2006;4:2569-75. (Pubitemid 44741550)
48. Chambers J, Fusi L, Malik I, et al. Association of maternal endothelial dysfunction with preeclampsia. J Am Med Assoc 2001;285:1607-12. (Pubitemid 32240253)
49. Landi B, Tranquilli A. HELLP syndrome and placental inflammatory pathology. Minerva Ginecol 2008;60:389-98.
50. Barden A. Pre-eclampsia: contribution of maternal constitutional factors and the consequences for cardiovascular health. Clin Exp Pharmacol Physiol 2006;2006: 826-30. (Pubitemid 44215138)
51. Bellamy L, Casas J, Hingorani A, Williams D. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and metaanalysis. Br Med J 2007;335:974-86.
52. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. J Hypertens 2005;23:233-46.
53. Ray J, Vermeulen M, Schull M, Redelmeier D. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005;366:1797-803. (Pubitemid 41642644)
54. Wierzbicki AS, Chowienczyk PJ, Cockcroft JR, et al. Cardiovascular risk factors and endothelial dysfunction. Clin Sci 2004;107:609-15. (Pubitemid 39627208)
55. Wolf M, Hubel CA, Lam C, et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metabol 2004;89:6239-43. (Pubitemid 39628439)
56. Owens M, Martin Jr. J, Wallace K, et al. Postpartum thrombotic mircoangiopathic syndrome. Transfusion Apheresis Sci 2013;48:51-7.
57. Steinborn A, Haensch G, Mahnke K, et al. Distinct subsets of regulatory T cells during pregnancy: is the imbalance of these subsets involved in the pathogenesis of preeclampsia Clin Immunol 2008;129:401-12.
58. Steinborn A, Schmitt E, Kisielewicz A, et al. Pregnancy-associated diseases are characterized by the composition of the systemic regulatory T cell (Treg) pool with distinct subsets of Tregs. Clin Exp Immunol 2011;167:84-98.
59. Dwivedi V, Tousif S, Bhattacharya D, et al. Transforming growth factor-beta protein inversely regulates in vivo differentiation of interleukin-17 (IL-17) producing CD4+ and CD8+ T cells. J Biol Chem 2012;287:2943-7.
60. He D, Wi L, Kim H, et al. CD8+ IL-17-producing t cells are important in effector functions for the elicitation of contact hypersensitivity responses. J Immunol 2006; 177:6852-8. (Pubitemid 44715050)